AstraZeneca remains a strong long-term Buy due to its robust product lineup and promising pipeline, aiming for $80 billion in revenues by 2030. The company currently has 14 blockbuster drugs and expects up to 12 more from its pipeline by decade's end. Recent wins in oncology, respiratory, and immunology offset setbacks like the eplontersen ATTR-CM study failure and Farxiga's US patent expiration. Analysts expect mid-to-high single-digit revenue growth and low double-digit core EPS growth in Q3 2026, with strong operating margins, signaling continued financial strength.
AstraZeneca shares are trading at USD 171.03 on Pluang, down 0.89% in the last day, with a market cap of $269.64 billion. As of Oct 23, 2026 22:51 WIB, most Pluang users are selling AstraZeneca, with 78% of order activity on the platform being sell orders.
Jefferies estimates a 59% probability that AstraZeneca's kidney drug zibotentan will succeed in the phase 3 ZENITH-HP trial, with results expected in the first half of 2027. The trial tests zibotentan combined with Farxiga in patients with high prote...
Oracle and AstraZeneca have entered a collaboration to combine AstraZeneca's scientific expertise with Oracle's AI, cloud, and real-world data capabilities. The partnership aims to accelerate clinical trials by helping clinicians identify eligible pa...
